Compare MCK & PFE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MCK | PFE |
|---|---|---|
| Founded | 1833 | 1849 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Pharmaceuticals | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 98.5B | 147.6B |
| IPO Year | 1995 | 2013 |
| Metric | MCK | PFE |
|---|---|---|
| Price | $873.79 | $27.98 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 14 |
| Target Price | ★ $952.92 | $29.29 |
| AVG Volume (30 Days) | 933.9K | ★ 33.5M |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | 0.40% | ★ 6.55% |
| EPS Growth | ★ 49.22 | N/A |
| EPS | ★ 5.15 | 0.43 |
| Revenue | ★ $112,084,000,000.00 | $62,579,000,000.00 |
| Revenue This Year | $14.94 | N/A |
| Revenue Next Year | $8.21 | N/A |
| P/E Ratio | $166.78 | ★ $65.23 |
| Revenue Growth | ★ 3.11 | N/A |
| 52 Week Low | $673.38 | $23.59 |
| 52 Week High | $999.00 | $28.75 |
| Indicator | MCK | PFE |
|---|---|---|
| Relative Strength Index (RSI) | 55.36 | 69.69 |
| Support Level | $800.61 | $24.90 |
| Resistance Level | $900.58 | $28.75 |
| Average True Range (ATR) | 26.95 | 0.54 |
| MACD | -3.79 | 0.16 |
| Stochastic Oscillator | 46.30 | 85.96 |
McKesson is one of three leading pharmaceutical wholesalers in the US engaged in sourcing and distributing branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with Cencora and Cardinal Health, the three account for over 90% of the US pharmaceutical wholesale industry. Outside the US market, McKesson engages in pharmaceutical wholesale and distribution in Canada. Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndaqel and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.